We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341371

CAS#: 101961-60-8

Description: Valanimycin is a biochemical.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-06-06. Prices are subject to change without notice.

Valanimycin is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 341371
Name: Valanimycin
CAS#: 101961-60-8
Chemical Formula: C7H12N2O3
Exact Mass: 172.0848
Molecular Weight: 172.184
Elemental Analysis: C, 48.83; H, 7.03; N, 16.27; O, 27.88

Synonym: Valanimycin.

IUPAC/Chemical Name: 2-Propenoic acid, 2-((2-methylpropyl)-ONN-azoxy)-


InChi Code: InChI=1S/C7H12N2O3/c1-5(2)4-9(12)8-6(3)7(10)11/h5H,3-4H2,1-2H3,(H,10,11)/b9-8-

SMILES Code: C=C(/N=[N+](CC(C)C)\[O-])C(O)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Mingyar E, Novakova R, Knirschova R, Feckova L, Bekeova C, Kormanec J. Unusual features of the large linear plasmid pSA3239 from Streptomyces aureofaciens CCM 3239. Gene. 2018 Feb 5;642:313-323. doi: 10.1016/j.gene.2017.11.046. Epub 2017 Nov 17. PubMed PMID: 29155332.

2: Moutiez M, Belin P, Gondry M. Aminoacyl-tRNA-Utilizing Enzymes in Natural Product Biosynthesis. Chem Rev. 2017 Apr 26;117(8):5578-5618. doi: 10.1021/acs.chemrev.6b00523. Epub 2017 Jan 6. Review. PubMed PMID: 28060488.

3: Verdel-Aranda K, López-Cortina ST, Hodgson DA, Barona-Gómez F. Molecular annotation of ketol-acid reductoisomerases from Streptomyces reveals a novel amino acid biosynthesis interlock mediated by enzyme promiscuity. Microb Biotechnol. 2015 Mar;8(2):239-52. doi: 10.1111/1751-7915.12175. Epub 2014 Oct 9. PubMed PMID: 25296650; PubMed Central PMCID: PMC4353338.

4: Garg RP, Parry RJ. Regulation of valanimycin biosynthesis in Streptomyces viridifaciens: characterization of VlmI as a Streptomyces antibiotic regulatory protein (SARP). Microbiology. 2010 Feb;156(Pt 2):472-83. doi: 10.1099/mic.0.033167-0. Epub 2009 Nov 5. PubMed PMID: 19892763; PubMed Central PMCID: PMC2890085.

5: Garg RP, Alemany LB, Moran S, Parry RJ. Identification, characterization, and bioconversion of a new intermediate in valanimycin biosynthesis. J Am Chem Soc. 2009 Jul 22;131(28):9608-9. doi: 10.1021/ja901243p. PubMed PMID: 19548668; PubMed Central PMCID: PMC2726733.

6: Garg RP, Qian XL, Alemany LB, Moran S, Parry RJ. Investigations of valanimycin biosynthesis: elucidation of the role of seryl-tRNA. Proc Natl Acad Sci U S A. 2008 May 6;105(18):6543-7. doi: 10.1073/pnas.0708957105. Epub 2008 May 1. PubMed PMID: 18451033; PubMed Central PMCID: PMC2373340.

7: Garg RP, Gonzalez JM, Parry RJ. Biochemical characterization of VlmL, a Seryl-tRNA synthetase encoded by the valanimycin biosynthetic gene cluster. J Biol Chem. 2006 Sep 15;281(37):26785-91. Epub 2006 Jul 20. PubMed PMID: 16857674.

8: Tao T, Alemany LB, Parry RJ. Valanimycin biosynthesis: investigations of the mechanism of isobutylhydroxylamine incorporation. Org Lett. 2003 Apr 17;5(8):1213-5. PubMed PMID: 12688722.

9: Garg RP, Ma Y, Hoyt JC, Parry RJ. Molecular characterization and analysis of the biosynthetic gene cluster for the azoxy antibiotic valanimycin. Mol Microbiol. 2002 Oct;46(2):505-17. PubMed PMID: 12406225.

10: Skae P, Parry RJ. Determination of the stereochemistry of hydride transfer from NADPH to FAD catalyzed by VlmR, a flavin reductase from the valanimycin biosynthetic pathway. Org Lett. 2001 Apr 19;3(8):1117-9. PubMed PMID: 11348173.

11: Ma Y, Patel J, Parry RJ. A novel valanimycin-resistance determinant (vlmF) from Streptomyces viridifaciens MG456-hF10. Microbiology. 2000 Feb;146 ( Pt 2):345-52. PubMed PMID: 10708373.

12: Parry RJ, Li W. An NADPH:FAD oxidoreductase from the valanimycin producer, Streptomyces viridifaciens. Cloning, analysis, and overexpression. J Biol Chem. 1997 Sep 12;272(37):23303-11. PubMed PMID: 9287340.

13: Parry RJ, Li W. Purification and characterization of isobutylamine N-hydroxylase from the valanimycin producer Streptomyces viridifaciens MG456-hF10. Arch Biochem Biophys. 1997 Mar 1;339(1):47-54. PubMed PMID: 9056232.

14: Parry RJ, Li W, Cooper HN. Cloning, analysis, and overexpression of the gene encoding isobutylamine N-hydroxylase from the valanimycin producer, Streptomyces viridifaciens. J Bacteriol. 1997 Jan;179(2):409-16. PubMed PMID: 8990292; PubMed Central PMCID: PMC178710.

15: Yamato M, Umezawa H, Sakata N, Moriya Y, Hori M. Valanimycin acts on DNA in bacterial cells. J Antibiot (Tokyo). 1987 Apr;40(4):558-60. PubMed PMID: 3294774.

16: Yamato M, Takeuchi T, Umezawa H, Sakata N, Hayashi H, Hori M. Biosynthesis of valanimycin. J Antibiot (Tokyo). 1986 Sep;39(9):1263-9. PubMed PMID: 3781925.

17: Yamato M, Iinuma H, Naganawa H, Yamagishi Y, Hamada M, Masuda T, Umezawa H, Abe V, Hori M. Isolation and properties of valanimycin, a new azoxy antibiotic. J Antibiot (Tokyo). 1986 Feb;39(2):184-91. PubMed PMID: 3754251.